V enous thromboembolism (VTE) is a common lifethreatening complication in patients undergoing neurosurgical procedures. The incidence of deep venous thrombosis (DVT) in this patient population without prophylaxis has been reported to be as high as 34% 3 in some studies, with a mean of 16% across several historical articles. 4 The length of neurosurgical procedures, delayed ambulation, lengthy hospital stays, and comorbid conditions place this subset of patients at higher risk for VTE. 3, 18, 19, 28, 29 An epidemiological report from 1994 estimated the rate of pulmonary embolism (PE) in neurosurgically treated patients at 0%-5%, with a mortality rate ranging from 9% to 50%.
intraspinal hemorrhage in the postoperative period persists, limiting the effective use of VTE chemoprophylaxis despite a large body of growing evidence supporting its efficacy. The literature has mixed information with differing levels of evidence on this topic (Table 1 ). Iorio and Agnelli performed a systematic review 16 years ago that included 4 randomized controlled trials (RCTs) showing a protective benefit from chemical VTE prophylaxis (OR 0.48, p < 0.001) and no significant bleeding complications (OR 1.72, p = 0.24). Eight years later, Collen et al. performed a systematic review that included studies without control groups and retrospective studies, with similar results. Glotzbecker et al. and Schuster et al. performed systematic reviews, which were severely limited because they made no formal comparisons (Glotzbecker) , used only retrospective studies (Glotzbecker) , or had only 2 articles included in the final analysis (Schuster) . The latest systematic review was performed 5 years ago by Hamilton et al., and it found a protective benefit (OR 0.58, p < 0.001) from a total of 6 RCTs without bleeding complications (p = 0.45).
Although each of these systematic reviews performed over the past 16 years provided valuable information, each study has notable limitations, as summarized in Table 1 . Thus, the uncertainty of VTE chemoprophylaxis in neurosurgically treated patients persists. Therefore, the purpose of this study was to review and analyze the most powerful and current information evaluating this topic.
The purpose of this study was to provide an updated systematic review and meta-analysis of neurosurgically treated patients receiving chemical prophylaxis to provide the neurosurgeon with concise, up-to-date information on the risks and benefits of chemical VTE prophylaxis.
Methods
This study was conducted using the Assessment of the Methodological Quality of Systematic Reviews (AM-STAR) measurement tool 31 and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 24 
Research Question
The research question for this study was the following: are the rates of VTE and bleeding complications different in patients undergoing cranial and spinal surgery when using pharmacological prophylaxis compared with placebo or mechanical prophylaxis alone?
Search Strategy
The systematic search strategy involved a search of multiple electronic databases, bibliographies of relevant articles, and consultation with the senior author. In February of 2016, we electronically searched PubMed/MED-LINE, Clinicaltrials.gov, EMBASE, Google Scholar, The Cochrane Library, and Scopus to find English-language articles (excluding gray literature) with no time-frame restrictions.
The following terms in various combinations were used: "Enoxaparin"; "Heparin"; "Neurosurgery"; "Thromboembolism"; and "Thromboprophylaxis." Two independent researchers (i.e., coauthors on this study), along with librarians at our academic institution, conducted independent literature searches. If there was any question as to the eligibility of an article, consensus was reached through discussion with the senior author. When necessary, additional contact was made with the authors of the included articles to confirm data. 
Inclusion Criteria, Data Extraction, End Points, Definitions
The goals of the search were to find articles that met the following inclusion criteria: 1) described a prospective study detailing a group of postoperative, neurosurgically treated, adult patients (> 18 years of age) who received chemical VTE prophylaxis; 2) described another group treated with placebo or mechanical prophylaxis; 3) had the use of prophylactic medication as the main treatment difference between the 2 groups; and 4) reported the number of patients and number of events for each group. Thus, noncomparison studies, case reports, and pediatric and retrospective reports were excluded.
Two coauthors of this study (N.R.K. and P.G.P.) screened all potential articles and extracted data independently. The data extracted from each article included the following: 1) dose and type of chemoprophylaxis; 2) total number of participants per group; 3) inclusion and exclusion criteria; 4) rates of VTE in both groups; 4) cointerventions performed along with chemical prophylaxis; 5) the modality used to diagnose VTE; 6) length of follow-up period; and 7) major and minor bleeding complications. Major bleeding was defined as a hemorrhage that changed the morbidity or mortality outcome of the patient or required a return to the operating room. Minor bleeding complications were defined as a drop in hematocrit, microhematuria, or other similar scenarios that did not alter the care of the patient as defined by the respective authors.
The level of evidence for each study was evaluated using the Oxford Centre for Evidence-Based Medicine (OCEBM) guidelines (http://www.cebm.net/ocebmlevels-of-evidence/). Study quality (i.e., assessment of bias within individual studies) was determined using the scale of Jadad et al. 17 for RCTs. Disagreements among any of the above-mentioned data points were resolved through discussion among the authors.
Meta-Analysis
For each study, the numbers of VTE events in patients treated with chemical prophylaxis and placebo were identified and an OR was calculated. The overall OR was computed using the method of DerSimonian and Laird. 6 A random-effects meta-analysis was performed on the selected studies. A random-effects model, in contrast to a fixed-effects model, does not assume that the relative risk is the same across studies and yields a more conservative estimate of effect. Heterogeneity between studies was assessed by the Cochran Q and I 2 statistic. Heterogeneity was considered statistically significant when the p value derived from Cochran Q was < 0.1. For the qualitative interpretation of heterogeneity, I
2 values of at least 50% are usually considered to represent substantial heterogeneity, whereas values of at least 75% indicate considerable heterogeneity, according to the Cochrane Handbook.
19 Publication bias (i.e., assessment of bias across studies) was graphically evaluated using a funnel plot.
8,32,33

Results
Our search strategy initially identified 3944 articles (Fig. 1) . After excluding duplicate studies and articles not directly related to our hypothesis, a total of 32 articles remained. Of these, 20 were excluded for being retrospective or not related to the study question, 3 articles 11,34 were pediatric reports, and 4 articles 2,10,21,22 did not have a controlled placebo group. This left a total of 5 articles 1, 5, 13, 25 for inclusion. After searching the bibliographies of all articles, 4 additional papers 3, 7, 12, 20, 23 were identified for inclusion.
Characteristics of Eligible Studies
The overall quality of included studies was good. All of the included articles except for one 7 were RCTs. Of these, all but 2 articles 3,20 were double-blinded. The Jadad score was on average moderate, at 3 ± 1 of 5. Three studies used heparin as the treatment drug and 6 studies used low-molecular-weight heparin (LMWH) ( Table 2 ). Each article was evaluated for quality of evidence using the OCEBM grading system, and all articles were found to be Level 2 of 5. There were 2 articles dedicated only to patients with spine disorders. Three articles included both patients with spine and those with cranial disease; however, only a mi- BID = twice a day; DHE = dihydroergotamine; FU = follow-up; HTN = hypertension; Hx = history; IV = intravenous; LE = lower extremity; meds = medication; NA = not applicable; prospect = prospective; prox = proximal; pts = patients; SCD = sequential compression device; SCI = spinal cord injury; SQ = subcutaneous; TID = thrice a day; Tx = treatment; VQ = ventilation/perfusion. 
Meta-Analysis
Deep Venous Thrombosis A total of 1232 patients were included. The rate of DVT in the treatment group was 76/604 (12.6%), and it was 135/628 (21.5%) in the control group. A meta-analysis comparing chemoprophylaxis with placebo in the prevention of DVT showed a significant benefit from chemical prophylaxis (OR 0.51, 95% CI 0.37-0.71; p < 0.0001) (Fig.  2) . The absolute risk reduction was 9% and the relative risk reduction was 42%. The number needed to treat to prevent 1 episode of DVT by using chemoprophylaxis compared with placebo was 11. The I 2 statistic of 0% indicates no significant heterogeneity in these results. This finding continues to hold true in a subset analysis that included only patients with cranial disorders (OR 0.38, p = 0.05).
Major Intracranial Hemorrhage
A total of 1305 patients were included. The rate of major intracranial hemorrhage (ICH) in the treatment group was 18/669 (2.7%), and it was 10/636 (1.6%) in the control group. A meta-analysis comparing chemoprophylaxis with placebo showed no significant increase in the rate of major ICH (OR 1.42, 95% CI 0.61-3.30; p = 0.60) (Fig. 3) . The I 2 statistic of 0% indicates no significant heterogeneity in these results.
Major Extracranial Hemorrhage
A total of 1276 patients were included. The rate of major extracranial hemorrhage (ECH) in the treatment group was 4/631 (0.6%), and it was 5/645 (0.8%) in the control group. A meta-analysis comparing chemoprophylaxis with placebo showed no significant increase in the rate of major ICH (OR 0.98, 95% CI 0.29-3.36; p = 0.98) (Fig. 4) . The I 2 statistic of 0% indicates no significant heterogeneity in these results.
Minor Bleeding Complications
A total of 1273 patients were included. The rate of minor ECH in the treatment group was 23/633 (3.6%), and it was 17/640 (2.6%) in the control group. A meta-analysis comparing chemoprophylaxis with placebo showed no significant increase in the rate of minor ECH (OR 1.28, 95% CI 0.50-3.24; p = 0.60) (Fig. 5) . The I 2 statistic of 33% suggests minimal heterogeneity in these results.
Spinal Hemorrhagic Complications
The 2 articles that included only spine patients were analyzed to specifically identify if any major spinal hemorrhagic complications were distinguished in the results. The only major spinal hemorrhagic complication, identified by Hamidi and Riazi, 13 occurred as a result of a laceration of the jugular vein during drain placement (not related to chemoprophylaxis). The other spinal study, by Gruber et al., reported 2 wound hematomas in the placebo group and 2 in the chemoprophylaxis group, and the only minor bleed- ing complication was increased postoperative drain output in 1 patient. 12 Additionally, the aforementioned 3 articles, which included a minor proportion of spine patients, did not identify any major spinal hemorrhagic complications in their results.
Publication Bias
The funnel plot suggests an absence of publication bias, given its overall symmetrical distribution (Fig. 6) . The remaining funnel plots for major ICH, ECH, and minor bleeding complications were all symmetrical.
Sensitivity Analysis
A sensitivity analysis using the leave-one-out method 26 was performed by removing each of the first of K studies and conducting the meta-analysis on the remaining K -1 studies until there were K distinct meta-analyses. This was performed on each unique outcome to confirm robustness of the analysis. We did not find a significant difference among any of the outcomes evaluated using this method.
Postoperative Subset Analysis
Only 1 study meeting the criteria included patients who had not undergone surgery. 20 A subset analysis leaving out this study showed no significant change in the results: the OR for VTE was 0.5 (CI 0.35-0.72, p = 0.0002); for major ICH it was 1.47 (CI 0.61-3.57, p = 0.39); for major ECH it was 0.81 (CI 0.21-3.06, p = 0.76); and for minor ICH it was 1.97 (CI 0.87-4.45, p = 0.1).
Discussion
Patients requiring cranial and spinal surgery present a unique situation of elevated risk for VTE but also high risk for disastrous outcomes should bleeding complications occur in eloquent areas of the brain or spinal cord. Chemical prophylaxis for VTE prevention is an issue neurosurgeons are confronted with on a daily basis. The core of this concern boils down to the following question: does the risk of VTE and its consequences outweigh the risk of potentially catastrophic hemorrhagic complications possible with chemoprophylaxis? The purpose of this study was to critically evaluate the literature and provide an updated systematic review to evaluate both the efficacy of VTE prevention and the risk of bleeding complications when using chemoprophylaxis in patients with neurosurgical diagnoses who are undergoing cranial or spinal surgery.
Five prior systematic reviews concerning this topic exist (Table 1) . A meta-analysis of 4 trials 1, 3, 23, 25 by Iorio and Agnelli in 2000 16 found a significant decrease in VTE when using chemoprophylaxis (OR 0.48, p < 0.001). They also found a nonsignificant relative increased risk of major bleeding (OR 1.72, p = 0.24).
Another meta-analysis by Collen et al. from 2008 evaluated both mechanical and chemical prophylaxis. 4 They included both articles without control groups and retrospective series. They concluded that there was no difference in the rates of ICH and that there was a decrease in DVT when using chemoprophylaxis. gery articles and estimated an overall DVT risk of 2.1%. However, this review included both retrospective and prospective articles. It also included different modalities of prophylaxis and did not provide a concrete comparison of the risks and benefits of chemoprophylaxis to discernible control groups. 9 A review in 2010 by Schuster et al. analyzed only elective thoracolumbar spinal surgeries and included only 2 articles, one of which used Coumadin (warfarin) 27 as the chemoprophylaxis agent and another 12 that is included in our current analysis. This review concluded that the incidence of DVT and PE is very low, and did not recommend the use of chemical prophylaxis. 30 A review in 2011 by Hamilton et al. looked specifically at RCTs of elective cranial surgeries, examining chemoprophylaxis versus placebo. They found 6 RCTs 1,3,5,7,23,25 that showed a significant risk reduction of VTE with use of chemoprophylaxis (OR 0.58, p < 0.001), in conjunction with a nonsignificant increase in the incidence of associated ICH in the treatment groups. 15 In the current analysis, we provide an updated comparison of chemical versus mechanical prophylaxis or placebo for VTEs for patients undergoing cranial or spinal surgery, and evaluated potential benefits and hemorrhagic complications. In comparison with prior systematic reviews, our study has included 3 studies that were not included in the most recent update in 2011, 15 and 5 more than the original systematic review on this topic. 16 Additionally, only prospective studies were included in the present study, compared with the systematic reviews performed by Glotzbecker et al. 9 and Collen et al. 4 ( Table 1) . We include both cranial and spinal procedures to estimate the efficacy of VTE prevention ( Table 2) . Several of these articles included patients with both cranial and spinal disorders, 1, 20, 25 whereas others did not. 3, 5, 7, 12, 13, 23 We also include only prospective studies that clearly delineate a comparison of a nonchemical control group or placebo. Our analysis of included studies suggests a significant benefit to using chemical prophylaxis in the prevention of VTE (Fig. 2) . The findings in this study are in general agreement with the prior estimates from pooled analysis. 1, 15 We also found a nonsignificant increase in the rate of major ICH, no difference in major ECH, and a nonsignificant increase in minor bleeding complications (Figs. 3-5 ). The overall rates of bleeding complications in treatment and placebo arms are listed by study in Table 3 .
Limitations of the Study
The strengths of the recommendations from a metaanalysis are only as robust as the quality of articles from which they are derived. The majority of articles included in this analysis were blinded RCTs with moderate quality. However, the population of patients, dosage and type of chemoprophylaxis, timing of chemoprophylaxis, and methods of VTE detection were heterogeneous. Although this study provides an estimate of the risks and benefits of using chemoprophylaxis in a general neurosurgical population, these findings cannot be applied to unique groups of patients who may be at a higher risk versus those at a lower risk-for example, a patient with a ruptured aneurysm compared with a patient undergoing an uncomplicated elective lumbar discectomy. More research and RCTs are needed to further define the optimal use of chemoprophylaxis in specific neurosurgical subpopulations. 
Study Implications
Our study provides an up-to-date evaluation of the literature from across the world of the general estimate of the risks and benefits of using chemoprophylaxis in patients undergoing cranial or spinal procedures. We found, based on moderate-to-good quality of evidence trials, that chemoprophylaxis is beneficial in preventing VTE while resulting in no statistically significant increase in bleeding complications (both minor and major).
Conclusions
Based on the moderate-to-good quality of evidence, chemoprophylaxis is beneficial in preventing VTEs in patients undergoing management of cranial or spinal pathology, with no significant increase in either major or minor bleeding complications. The adverse impact of VTE in untreated patients appears to outweigh that of hemorrhage in patients receiving chemoprophylaxis. Further research is needed to determine whether this conclusion holds true for more specific subpopulations, and for the optimal timing for initiation of chemoprophylaxis.
